Neuronetics logo
Neuronetics STIM
$ 1.65 8.55%

Quarterly report 2025-Q3
added 11-04-2025

report update icon

Neuronetics Financial Statements 2011-2025 | STIM

Annual Financial Statements Neuronetics

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

121 M 85.1 M 293 M 71.3 M 151 M - - - - - - -

Shares

26.9 M 25.5 M 18.8 M 18.4 M 8.95 M - - - - - - -

Historical Prices

4.51 3.34 15.5 2.9 17.4 - - - - - - -

Net Income

-37.2 M -31.2 M -27.5 M -29 M -24.1 M -16.1 M -11.2 M - - - - -

Revenue

65.2 M 55.3 M 49.2 M 62.7 M 52.8 M 40.4 M 34.2 M - - - - -

Cost of Revenue

15.5 M 11.7 M 11.6 M 15.4 M 12.4 M 9.63 M 6.62 M - - - - -

Gross Profit

49.7 M 43.7 M 37.7 M 47.3 M 40.3 M 30.8 M 27.6 M - - - - -

Operating Income

-35.1 M -27.6 M -22.3 M -26.9 M -19.8 M -13.6 M -9.34 M - - - - -

Interest Expense

4.25 M 4.02 M 4.52 M 3.68 M 3.69 M 2.81 M 1.84 M - - - - -

EBITDA

-33.5 M -26.5 M -21.4 M -25.9 M -19 M -13 M -8.66 M - - - - -

Operating Expenses

84.8 M 71.2 M 60 M 74.2 M 60.2 M 44.4 M 36.9 M - - - - -

General and Administrative Expenses

25.5 M 25.6 M 18.2 M 17.5 M 13.7 M 8.57 M 6.93 M - - - - -

All numbers in USD currency

Quarterly Income Statement Neuronetics

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

67.3 M 66.2 M 61.5 M 55.7 M 30.3 M 30.1 M 29.5 M 29.1 M 28.9 M 28.6 M 28 M 27.3 M 27 M 26.8 M 26.6 M 26.4 M 26.3 M 25.9 M 25.2 M 19 M 18.9 M 18.7 M 18.7 M 18.6 M 18.5 M 18.4 M 18 M 17.7 M 17.4 M 245 K 226 K 211 K 194 K 173 K 167 K - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-9.04 M -10.1 M -12.7 M - -13.3 M -9.83 M -7.87 M - -9.39 M -4.9 M -10.5 M - -7.61 M -10.4 M -10.8 M - -8.15 M -7.52 M -7.88 M -3.66 M -3.42 M -7.76 M -12.6 M -7.55 M -6.87 M -7.09 M -7.53 M -6.14 M -4.96 M -7.5 M -5.5 M -4.92 M -3.75 M -2.87 M -4.51 M - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

37.3 M 38.1 M 32 M - 18.5 M 16.4 M 17.4 M - 17.9 M 17.6 M 15.5 M - 16.5 M 16.3 M 14.2 M - 13.8 M 14.2 M 12.3 M 15.6 M 12.4 M 9.74 M 11.5 M 17.4 M 16 M 16.6 M 12.7 M 15.6 M 13.7 M 13.3 M 10.2 M 12.1 M 10.5 M 10.3 M 7.53 M - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

20.2 M 20.4 M 16.2 M - 4.53 M 4.27 M 4.33 M - 6.12 M 4.84 M 4.14 M - 3.57 M 4.04 M 3.48 M - 3.14 M 2.75 M 2.22 M 3.76 M 2.66 M 2.32 M 2.81 M 4.22 M 4.19 M 4.17 M 2.81 M 3.71 M 3.03 M 3.24 M 2.46 M 2.96 M 2.64 M 2.5 M 1.54 M - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

17.1 M 17.8 M 15.7 M - 14 M 12.2 M 13.1 M - 11.8 M 12.8 M 11.4 M - 12.9 M 12.3 M 10.7 M - 10.7 M 11.5 M 10.1 M 11.8 M 9.79 M 7.42 M 8.66 M 13.1 M 11.8 M 12.4 M 9.92 M 11.9 M 10.7 M 10 M 7.7 M 9.15 M 7.86 M 7.81 M 5.99 M - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-7.32 M -8.06 M -11 M - -7.73 M -8.51 M -6.86 M - -8.87 M -7.35 M -9.91 M - -7.45 M -9.8 M -10.1 M - -7.18 M -6.56 M -6.91 M -2.66 M -2.42 M -6.86 M -10.4 M -6.94 M -6.33 M -6.61 M -7.06 M -5.66 M -4.33 M -5.24 M -4.6 M -4.23 M -2.81 M -2.58 M -3.99 M - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

2.21 M 1.97 M 1.92 M - 1.72 M 1.98 M 1.83 M - 1.18 M 1.14 M 1.25 M - 1.06 M 1 M 978 K - 993 K 977 K 985 K 1.01 M 1 M 986 K 1.52 M 905 K 930 K 931 K 919 K 939 K 928 K 900 K 921 K 740 K 807 K 711 K 550 K - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-6.82 M -7.56 M -10.1 M - -7.23 M -7.91 M -6.3 M - -8.37 M -6.85 M -9.39 M - -7.05 M -9.5 M -9.82 M - -6.41 M -6.26 M -6.63 M -2.66 M -1.68 M -6.32 M -10.1 M -6.94 M -5.56 M -6.15 M -6.85 M -5.66 M -3.66 M -4.77 M -4.47 M -4.23 M -2.36 M -2.27 M -3.99 M - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

24.4 M 25.8 M 26.8 M - 21.7 M 20.7 M 19.9 M - 20.6 M 20.1 M 21.3 M - 20.4 M 22.1 M 20.8 M - 17.8 M 18 M 17 M 14.5 M 12.2 M 14.3 M 19 M 20.1 M 18.1 M 19 M 17 M 17.6 M 15 M 15.2 M 12.3 M 13.4 M 10.7 M 10.4 M 9.98 M - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

11.1 M 12.2 M 13.1 M - 7.44 M 6.15 M 5.96 M - 6.34 M 6.2 M 6.61 M - 6.39 M 6.36 M 6.38 M - 6.44 M 6.68 M 6.1 M 4.73 M 4.21 M 4.01 M 5.29 M 4.31 M 4.28 M 4.26 M 4.6 M 4.72 M 3.24 M 3.08 M 2.64 M 2.84 M 2.26 M 1.84 M 1.64 M - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Neuronetics STIM
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Neuronetics plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Brainsway Ltd. Brainsway Ltd.
BWAY
$ 16.64 -1.25 % $ 99.4 M israelIsrael
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 11.98 0.76 % $ 340 M israelIsrael
DexCom DexCom
DXCM
$ 66.7 -0.39 % $ 25.7 B usaUSA
Burning Rock Biotech Limited Burning Rock Biotech Limited
BNR
$ 16.71 6.1 % $ 180 M chinaChina
Exact Sciences Corporation Exact Sciences Corporation
EXAS
$ 101.53 0.03 % $ 18.8 B usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
BioNano Genomics BioNano Genomics
BNGO
$ 1.59 -1.91 % $ 2.02 M usaUSA
IQVIA Holdings IQVIA Holdings
IQV
$ 222.65 0.18 % $ 40.4 B usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Castle Biosciences Castle Biosciences
CSTL
$ 38.47 -0.41 % $ 1.07 B usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Danaher Corporation Danaher Corporation
DHR
$ 226.5 0.08 % $ 166 B usaUSA
Fulgent Genetics Fulgent Genetics
FLGT
$ 26.81 -1.22 % $ 811 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
Mettler-Toledo International Mettler-Toledo International
MTD
$ 1 415.66 1.58 % $ 30 B schweizSchweiz
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
Myriad Genetics Myriad Genetics
MYGN
$ 7.01 -2.77 % $ 635 M usaUSA
NeoGenomics NeoGenomics
NEO
$ 12.08 1.94 % $ 1.53 B usaUSA
Neogen Corporation Neogen Corporation
NEOG
$ 6.83 -0.51 % $ 1.48 B usaUSA
CareDx, Inc CareDx, Inc
CDNA
$ 19.96 -2.92 % $ 1.07 B usaUSA
Celcuity Celcuity
CELC
$ 102.35 -2.76 % $ 4.04 B usaUSA
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
$ 3.56 -0.7 % $ 114 K usaUSA
Co-Diagnostics Co-Diagnostics
CODX
$ 0.31 -9.02 % $ 9.1 M usaUSA
Pacific Biosciences of California Pacific Biosciences of California
PACB
$ 2.11 -0.71 % $ 535 M usaUSA
Quidel Corporation Quidel Corporation
QDEL
$ 28.87 0.24 % $ 1.22 B usaUSA
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
$ 26.56 -0.23 % $ 20 B niderlandNiderland
Guardant Health Guardant Health
GH
$ 104.86 2.73 % $ 12.9 B usaUSA
Precipio Precipio
PRPO
$ 24.68 -1.14 % $ 32 M usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
$ 45.24 0.04 % $ 10.1 B niderlandNiderland
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Sotera Health Company Sotera Health Company
SHC
$ 16.81 -0.15 % $ 4.75 B usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
Soleno Therapeutics Soleno Therapeutics
SLNO
$ 51.43 -1.1 % $ 2.07 B usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Illumina Illumina
ILMN
$ 134.29 -0.43 % $ 21.4 B usaUSA
Charles River Laboratories International Charles River Laboratories International
CRL
$ 196.55 1.82 % $ 10.1 B usaUSA
Quotient Limited Quotient Limited
QTNT
- -11.32 % $ 1.1 M schweizSchweiz
Thermo Fisher Scientific Thermo Fisher Scientific
TMO
$ 567.34 -0.76 % $ 217 B usaUSA
Trinity Biotech plc Trinity Biotech plc
TRIB
$ 1.08 0.93 % $ 61.9 M irlandaIrlanda
Twist Bioscience Corporation Twist Bioscience Corporation
TWST
$ 31.12 0.61 % $ 1.86 B usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 183.54 0.54 % $ 20.4 B usaUSA
Biodesix Biodesix
BDSX
$ 7.76 -1.15 % $ 1.01 B usaUSA